Last week, Venable scored an important victory in federal court on behalf of Ranbaxy in the first test of what limits may be placed on reverse payment antitrust deals among drugmakers to protect steady streams of revenue on popular drugs. The case against AstraZeneca and Ranbaxy challenged a 2008 settlement of a patent lawsuit that stalled sales of a cheaper version of Nexium in the U.S. until AstraZeneca's patents expired last May. The case is the first reverse payment antitrust suit to go to trial since the U.S. Supreme Court ruled in June 2013 that the Hatch-Waxman Act settlements could be challenged under federal antitrust law.
On December 10, 2014, Global Competition Review recognized Venable partner Doug Baldridge as its Litigator of the Week for his role in the victory. Discussing the complexity of the case, Baldridge, who led the Venable team, said, "There were complex issues floating around, but as I argued in the closing, in my view it’s a bunch of noise." Baldridge added that throughout the trial he "stayed consistent with the truth" and had high praise for the jury, saying, "This particular jury was the most attentive jury I've ever seen. No sleeping, no real boredom, at the edge of their seats listening all along, very conscientious." Baldridge also had particular praise for co-counsel and Venable partner Danielle Foley who he said "was instrumental in dealing with the ocean of motions filed by both sides throughout the trial."
In addition to Baldridge and Foley, the Venable team also included partner Lisa Jose Fales, associates Vincent Verrocchio, Paul Feinstein, Sarah Choi and Molly Cusson with Marta Markowska and Jeanne Mooney.